574 related articles for article (PubMed ID: 31838881)
1. Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Li JX; Huang JM; Jiang ZB; Li RZ; Sun A; Lai-Han Leung E; Yan PY
Integr Cancer Ther; 2019; 18():1534735419890020. PubMed ID: 31838881
[TBL] [Abstract][Full Text] [Related]
2. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge.
Yang Y; Yu Y; Lu S
Sci China Life Sci; 2020 Oct; 63(10):1499-1514. PubMed ID: 32303964
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
6. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
Zhang D; Huang J; Zhang C; Guan Y; Guo Q
Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):369-379. PubMed ID: 31196371
[TBL] [Abstract][Full Text] [Related]
7. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
8. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
[TBL] [Abstract][Full Text] [Related]
9. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.
Cree IA; Booton R; Cane P; Gosney J; Ibrahim M; Kerr K; Lal R; Lewanski C; Navani N; Nicholson AG; Nicolson M; Summers Y
Histopathology; 2016 Aug; 69(2):177-86. PubMed ID: 27196116
[TBL] [Abstract][Full Text] [Related]
12. [Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma].
Berghmans T; Grigoriu B; Sculier JP; Meert AP
Rev Mal Respir; 2018 Feb; 35(2):197-205. PubMed ID: 29395567
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
Schulz C; Gandara D; Berardo CG; Rosenthal R; Foo J; Morel C; Ballinger M; Watkins C; Chu P
Clin Lung Cancer; 2019 Nov; 20(6):451-460.e5. PubMed ID: 31375454
[TBL] [Abstract][Full Text] [Related]
14. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
Qiao M; Jiang T; Ren S; Zhou C
Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
Tan PS; Aguiar P; Haaland B; Lopes G
Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
Kumar R; Collins D; Dolly S; McDonald F; O'Brien MER; Yap TA
Curr Probl Cancer; 2017; 41(2):111-124. PubMed ID: 28214087
[TBL] [Abstract][Full Text] [Related]
17. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
Proto C; Ferrara R; Signorelli D; Lo Russo G; Galli G; Imbimbo M; Prelaj A; Zilembo N; Ganzinelli M; Pallavicini LM; De Simone I; Colombo MP; Sica A; Torri V; Garassino MC
Cancer Treat Rev; 2019 May; 75():39-51. PubMed ID: 30954906
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
[TBL] [Abstract][Full Text] [Related]
19. Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis.
El-Osta H; Jafri S
Immunotherapy; 2019 Feb; 11(3):189-199. PubMed ID: 30730276
[TBL] [Abstract][Full Text] [Related]
20. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
